News blog
Omega Diagnostics
- BY: Andrew Hore |
- POSTED: 13/02/2014 |
Omega Diagnostics has validated the manufacturing process for the Visitect CD4 and this will enable full commercialisation of the technology.
The Visitect CD4 tests the immune status of HIV patients. The low cost CD4 product can test a finger prick blood sample and provides a result in 40 minutes, which is faster than rival products. The first evaluations will be in Kenya and Mozambique. There will also be CE Mark studies.
Omega’s production facility can manufacture more than 7m of the devices
The share price rose 2.75p to 19.5p, which values Omega at £21.1m. The shares are trading on 16 times 2013-14 prospective earnings, falling to less than six times 2014-15 prospective earnings.
Download the latest AIM Journal from http://wwww.hubinvest.com/AIMPDFFebruary2014_53.pdf
© 2024 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
- Browse by issue
- All issues
- Popular tags
- All tags
- AIM Micro feeds
Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds
|